List of Publications by Year in descending order

211 papers	9,003 citations	53660 45 h-index	58464 82 g-index
215 all docs	215 docs citations	215 times ranked	10548 citing authors

#	Article	IF	Citations
1	Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 1153.	1.8	11
2	Local Accumulation of Lymphocytes in the Intima of Human Aorta Is Associated with Giant Multinucleated Endothelial Cells: Possible Explanation for Mosaicism of Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 1059.	1.8	3
3	The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets. International Journal of Molecular Sciences, 2022, 23, 931.	1.8	36
4	Atherosclerosis amelioration by allicin in raw garlic through gut microbiota and trimethylamine-N-oxide modulation. Npj Biofilms and Microbiomes, 2022, 8, 4.	2.9	29
5	Novel Models of Crohnâ€™s Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells. International Journal of Molecular Sciences, 2022, 23, 5141.	1.8	1
6	Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov. Biomedicines, 2022, 10, 1174.	1.4	6
7	Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 6954.	1.8	22
8	Aging of Vascular System Is a Complex Process: The Cornerstone Mechanisms. International Journal of Molecular Sciences, 2022, 23, 6926.	1.8	2
9	Effects of Metabolic Disorders in Immune Cells and Synoviocytes on the Development of Rheumatoid Arthritis. Metabolites, 2022, 12, 634.	1.3	2
10	The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy. International Journal of Molecular Sciences, 2022, 23, 7863.	1.8	14
11	An original biomarker for the risk of developing cardiovascular diseases and their complications: Telomere length. Toxicology Reports, 2021, 8, 499-504.	1.6	5
12	Role of Telomeres Shortening in Atherogenesis: An Overview. Cells, 2021, 10, 395.	1.8	13
13	Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Lowâ€Đensity Lipoproteins and Increasing Their Uptake by Macrophages. Journal of the American Heart Association, 2021, 10, e018756.	1.6	29
14	Two Subpopulations of Human Monocytes That Differ by Mitochondrial Membrane Potential. Biomedicines, 2021, 9, 153.	1.4	0
15	Autophagy and Mitophagy as Essential Components of Atherosclerosis. Cells, 2021, 10, 443.	1.8	23
16	Mutations of mtDNA in some Vascular and Metabolic Diseases. Current Pharmaceutical Design, 2021, 27, 177-184.	0.9	4
17	Immunopathology of Atherosclerosis and Related Diseases: Focus on Molecular Biology. International Journal of Molecular Sciences, 2021, 22, 4080.	1.8	23
18	Atherosclerosis as Mitochondriopathy: Repositioning the Disease to Help Finding New Therapies. Frontiers in Cardiovascular Medicine, 2021, 8, 660473.	1.1	12

#	Article	IF	Citations
19	Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside. Biomedicines, 2021, 9, 600.	1.4	26
20	Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines. International Journal of Molecular Sciences, 2021, 22, 7061.	1.8	37
21	Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. International Journal of Molecular Sciences, 2021, 22, 6949.	1.8	10
22	Recognition of Oxidized Lipids by Macrophages and Its Role in Atherosclerosis Development. Biomedicines, 2021, 9, 915.	1.4	36
23	Mitochondrial Dysfunction in Vascular Wall Cells and Its Role in Atherosclerosis. International Journal of Molecular Sciences, 2021, 22, 8990.	1.8	38
24	Macrophages and Foam Cells: Brief Overview of Their Role, Linkage, and Targeting Potential in Atherosclerosis. Biomedicines, 2021, 9, 1221.	1.4	33
25	Some Molecular and Cellular Stress Mechanisms Associated with Neurodegenerative Diseases and Atherosclerosis. International Journal of Molecular Sciences, 2021, 22, 699.	1.8	11
26	A Novel Insight at Atherogenesis: The Role of Microbiome. Frontiers in Cell and Developmental Biology, 2020, 8, 586189.	1.8	19
27	Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study. Biology, 2020, 9, 184.	1.3	3
28	Genetics of Arterial-Wall-Specific Mechanisms in Atherosclerosis: Focus on Mitochondrial Mutations. Current Atherosclerosis Reports, 2020, 22, 54.	2.0	4
29	Lipid Metabolism in Macrophages: Focus on Atherosclerosis. Biomedicines, 2020, 8, 262.	1.4	57
30	Impact of Mitochondrial DNA Mutations on Carotid Intima-Media Thickness in the Novosibirsk Region. Life, 2020, 10, 160.	1.1	4
31	Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations. Frontiers in Pharmacology, 2020, 11, 642.	1.6	28
32	Mitochondrial Dysfunction and DNA Damage in the Context of Pathogenesis of Atherosclerosis. Biomedicines, 2020, 8, 166.	1.4	40
33	The Diabetes Mellitusâ€“Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. International Journal of Molecular Sciences, 2020, 21, 1835.	1.8	469
34	Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis. Cells, 2020, 9, 584.	1.8	67
35	The Role of Mitochondria in Cardiovascular Diseases. Biology, 2020, 9, 137.	1.3	40
36	Data on association of mitochondrial heteroplasmy with carotid intima-media thickness in subjects from Russian and Kazakh populations. Data in Brief, 2020, 29, 105136.	0.5	7

#	Article	IF	Citations
37	Role of Phagocytosis in the Pro-Inflammatory Response in LDL-Induced Foam Cell Formation; a Transcriptome Analysis. International Journal of Molecular Sciences, 2020, 21, 817.	1.8	17
38	Lipidâ€based gene delivery to macrophage mitochondria for atherosclerosis therapy. Pharmacology Research and Perspectives, 2020, 8, e00584.	1.1	13
39	Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Responseâ€"What is First?. International Journal of Molecular Sciences, 2020, 21, 2716.	1.8	16
40	Clinical Effectiveness of a Combination of Black Elder Berries, Violet Herb, and Calendula Flowers in Chronic Obstructive Pulmonary Disease: The Results of a Double-Blinded Placebo-Controlled Study. Biology, 2020, 9, 83.	1.3	0
41	Medicinal Plants as a Potential and Successful Treatment Option in the Context of Atherosclerosis. Frontiers in Pharmacology, 2020, 11, 403.	1.6	34
42	Oxidative Stress and Antioxidants in Atherosclerosis Development and Treatment. Biology, 2020, 9, 60.	1.3	68
43	Possible Role of Mitochondrial DNA Mutations in Chronification of Inflammation: Focus on Atherosclerosis. Journal of Clinical Medicine, 2020, 9, 978.	1.0	23
44	Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. Frontiers in Pharmacology, 2020, 11, 613780.	1.6	142
45	Mitochondrion as a Selective Target for the Treatment of Atherosclerosis: Role of Mitochondrial DNA Mutations and Defective Mitophagy in the Pathogenesis of Atherosclerosis and Chronic Inflammation. Current Neuropharmacology, 2020, 18, 1064-1075.	1.4	43
46	Novel Approaches to Anti-atherosclerotic Therapy: Cell-based Models and Herbal Preparations (Review) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.6	0
47	The role of sialic acids in the initiation of atherosclerosis. Minerva Cardioangiologica, 2020, 68, 359-364.	1.2	5
48	Comparative analysis of the variability of carotid intima-media thickness in primary prevention populations of Moscow and Paris. American Journal of Cardiovascular Disease, 2020, 10, 463-472.	0.5	0
49	Foam cell formation and cholesterol trafficking and metabolism disturbances in atherosclerosis. Cor Et Vasa, 2019, 61, 48-55.	0.1	14
50	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. Current Medicinal Chemistry, 2019, 26, 1512-1524.	1.2	17
51	Changes in Mitochondrial Genome Associated with Predisposition to Atherosclerosis and Related Disease. Biomolecules, 2019, 9, 377.	1.8	25
52	The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. International Journal of Molecular Sciences, 2019, 20, 3561.	1.8	89
53	Immune-Inflammatory Responses in Atherosclerosis: The Role of Myeloid Cells. Journal of Clinical Medicine, 2019, 8, 1798.	1.0	45
54	Therapeutic effects of garlic in cardiovascular atherosclerotic disease. Chinese Journal of Natural Medicines, 2019, 17, 721-728.	0.7	31

#	Article	IF	Citations
55	Heteroplasmic Variants of Mitochondrial DNA in Atherosclerotic Lesions of Human Aortic Intima. Biomolecules, 2019, 9, 455.	1.8	13
56	Creation of Cybrid Cultures Containing mtDNA Mutations m.12315G>A and m.1555G>A, Associated with Atherosclerosis. Biomolecules, 2019, 9, 499.	1.8	8
57	Pericytes in Atherosclerosis. Advances in Experimental Medicine and Biology, 2019, 1147, 279-297.	0.8	16
58	Modern approaches for modelling dystonia and Huntington's disease in vitro and in vivo. International Journal of Experimental Pathology, 2019, 100, 64-71.	0.6	4
59	3. The significance of pericytes in health and disease: the role of pericytes with special focus on atherosclerosis. , 2019, , 34-52.		0
60	Sialidase activity in human pathologies. European Journal of Pharmacology, 2019, 842, 345-350.	1.7	60
61	Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 643-653.	1.2	19
62	Creation of Cultures Containing Mutations Linked with Cardiovascular Diseases using Transfection and Genome Editing. Current Pharmaceutical Design, 2019, 25, 693-699.	0.9	7
63	The role of monocytosis and neutrophilia in atherosclerosis. Journal of Cellular and Molecular Medicine, 2018, 22, 1366-1382.	1.6	48
64	The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Annals of Medicine, 2018, 50, 121-127.	1.5	299
65	Inhibition of sialidase activity as a therapeutic approach. Drug Design, Development and Therapy, 2018, Volume 12, 3431-3437.	2.0	37
66	Mitochondrial diseases caused by mtDNA mutations: a mini-review. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1933-1942.	0.9	49
67	Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. Journal of Molecular and Cellular Cardiology, 2018, 123, 159-167.	0.9	51
68	Response to: Comment on â€œRole of Mitochondrial Genome Mutations in Pathogenesis of Carotid Atherosclerosisâ€• Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-3.	1.9	1
69	Modified lipoproteins as biomarkers of atherosclerosis. Frontiers in Bioscience - Landmark, 2018, 23, 1422-1444.	3.0	18
70	Mitochondrial Genome Mutations Associated with Myocardial Infarction. Disease Markers, 2018, 2018, 1-6.	0.6	13
71	Data on association of mitochondrial heteroplasmy and cardiovascular risk factors: Comparison of samples from Russian and Mexican populations. Data in Brief, 2018, 18, 16-21.	0.5	11
72	Cybrid Models of Pathological Cell Processes in Different Diseases. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-6.	1.9	17

#	Article	IF	Citations
73	LDL and foam cell formation as the basis of atherogenesis. Current Opinion in Lipidology, 2018, 29, 279-284.	1.2	36
74	The phenomenon of atherosclerosis reversal and regression: Lessons from animal models. Experimental and Molecular Pathology, 2017, 102, 138-145.	0.9	29
75	How do macrophages sense modified low-density lipoproteins?. International Journal of Cardiology, 2017, 230, 232-240.	0.8	27
76	Analysis of Apolipoprotein B Protein of Circulating Multiple-Modified Low-Density Lipoprotein. International Journal of Angiology, 2017, 26, 049-052.	0.2	2
77	Macrophages and Their Contribution to the Development of Atherosclerosis. Results and Problems in Cell Differentiation, 2017, 62, 273-298.	0.2	17
78	Circulating desialylated low density lipoprotein. Cor Et Vasa, 2017, 59, e149-e156.	0.1	11
79	Mechanisms of foam cell formation in atherosclerosis. Journal of Molecular Medicine, 2017, 95, 1153-1165.	1.7	406
80	Role of lipids and intraplaque hypoxia in the formation of neovascularization in atherosclerosis. Annals of Medicine, 2017, 49, 661-677.	1.5	21
81	Genes associated with cholesterol accumulation in macrophages (transcriptome analysis). Atherosclerosis, 2017, 263, e117.	0.4	2
82	CD68/macrosialin: not just a histochemical marker. Laboratory Investigation, 2017, 97, 4-13.	1.7	447
83	Thrombospondins: A Role in Cardiovascular Disease. International Journal of Molecular Sciences, 2017, 18, 1540.	1.8	48
84	Cell-Based Models for Development of Antiatherosclerotic Therapies. BioMed Research International, 2017, 2017, 1-8.	0.9	2
85	Role of Mitochondrial Genome Mutations in Pathogenesis of Carotid Atherosclerosis. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-7.	1.9	31
86	Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	247
87	Calcifying Matrix Vesicles and Atherosclerosis. BioMed Research International, 2017, 2017, 1-7.	0.9	35
88	Use of Primary Macrophages for Searching Novel Immunocorrectors. Current Pharmaceutical Design, 2017, 23, 915-920.	0.9	3
89	Monocyte Activation in Immunopathology: Cellular Test for Development of Diagnostics and Therapy. Journal of Immunology Research, 2016, 2016, 1-9.	0.9	32
90	Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes. Stem Cells International, 2016, 2016, 1-7.	1.2	16

#	Article	IF	Citations
91	Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis. BioMed Research International, 2016, 2016, 1-13.	0.9	252
92	Antiatherosclerotic Efficacy of Nutraceuticals. , 2016, , 61-73.		0
93	The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in Atherosclerosis. International Journal of Molecular Sciences, 2016, 17, 193.	1.8	72
94	Anti-Atherosclerotic Effects of a Phytoestrogen-Rich Herbal Preparation in Postmenopausal Women. International Journal of Molecular Sciences, 2016, 17, 1318.	1.8	39
95	Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation. Transfusion Medicine and Hemotherapy, 2016, 43, 66-77.	0.7	38
96	Macrophageâ€mediated cholesterol handling in atherosclerosis. Journal of Cellular and Molecular Medicine, 2016, 20, 17-28.	1.6	375
97	Immune-inflammatory responses in atherosclerosis: Role of an adaptive immunity mainly driven by T and B cells. Immunobiology, 2016, 221, 1014-1033.	0.8	53
98	Organosulfur Compounds as Nutraceuticals. , 2016, , 555-568.		15
99	Dataset of mitochondrial genome variants associated with asymptomatic atherosclerosis. Data in Brief, 2016, 7, 1570-1575.	0.5	10
100	Links between atherosclerotic and periodontal disease. Experimental and Molecular Pathology, 2016, 100, 220-235.	0.9	94
101	Analysis of mitochondrial DNA heteroplasmic mutations A1555G, C3256T, T3336C, Đ¡5178Đ¸ G12315A, G13513A, G14459A, G14846Đ•and G15059A in CHD patients with the history of myocardial infarction. Experimental and Molecular Pathology, 2016, 100, 87-91.	0.9	20
102	Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential. Phytomedicine, 2016, 23, 1190-1197.	2.3	38
103	Cellular mechanisms of human atherosclerosis: Role of cell-to-cell communications in subendothelial cell functions. Tissue and Cell, 2016, 48, 25-34.	1.0	17
104	Anti-cytokine therapy for prevention of atherosclerosis. Phytomedicine, 2016, 23, 1198-1210.	2.3	24
105	Anti-atherosclerotic effects of garlic preparation in freeze injury model of atherosclerosis in cholesterol-fed rabbits. Phytomedicine, 2016, 23, 1235-1239.	2.3	23
106	Cell Composition of the Subendothelial Aortic Intima and the Role of Alpha-Smooth Muscle Actin Expressing Pericyte-Like Cells and Smooth Muscle Cells in the Development of Atherosclerosis. , 2015, , .		1
107	LDL electronegativity index: a potential novel index for predicting cardiovascular disease. Vascular Health and Risk Management, 2015, 11, 525.	1.0	23
108	Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy. Current Pharmaceutical Design, 2015, 21, 1172-1179.	0.9	17

#	Article	IF	Citations
109	Endothelial Barrier and Its Abnormalities in Cardiovascular Disease. Frontiers in Physiology, 2015, 6, 365.	1.3	184
110	Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling. BioMed Research International, 2015, 2015, 1-18.	0.9	139
111	Development of Antiatherosclerotic Drugs on the basis of Natural Products Using Cell Model Approach. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-11.	1.9	18
112	Mosaicism of Mitochondrial Genetic Variation in Atherosclerotic Lesions of the Human Aorta. BioMed Research International, 2015, 2015, 1-9.	0.9	34
113	Editorial (Thematic Issue: Mechanisms of Atherogenesis and Development of Anti-Atherosclerotic) Tj ETQq1 1 0.784314 rgBT /Overlock	0.9	5
114	Mitochondrial Aging: Focus on Mitochondrial DNA Damage in Atherosclerosis - A Mini-Review. Gerontology, 2015, 61, 343-349.	1.4	27
115	Heterogeneity of Tregs and the complexity in the IL-12 cytokine family signaling in driving T-cell immune responses in atherosclerotic vessels. Molecular Immunology, 2015, 65, 133-138.	1.0	8
116	Association of mutations in the mitochondrial genome with the subclinical carotid atherosclerosis in women. Experimental and Molecular Pathology, 2015, 99, 25-32.	0.9	13
117	Vascular stem/progenitor cells: current status of the problem. Cell and Tissue Research, 2015, 362, 1-7.	1.5	29
118	Mutations of mitochondrial genome in carotid atherosclerosis. Frontiers in Genetics, 2015, 6, 111.	1.1	10
119	Extracellular vesicles and atherosclerotic disease. Cellular and Molecular Life Sciences, 2015, 72, 2697-2708.	2.4	69
120	Phenomenon of individual difference in human monocyte activation. Experimental and Molecular Pathology, 2015, 99, 151-154.	0.9	11
121	Study of the activated macrophage transcriptome. Experimental and Molecular Pathology, 2015, 99, 575-580.	0.9	23
122	Quantitative analysis of the expression of caspase 3 and caspase 9 in different types of atherosclerotic lesions in the human aorta. Experimental and Molecular Pathology, 2015, 99, 1-6.	0.9	13
123	Association of mitochondrial mutations with the age of patients having atherosclerotic lesions. Experimental and Molecular Pathology, 2015, 99, 717-719.	0.9	11
124	Neutrophil's weapons in atherosclerosis. Experimental and Molecular Pathology, 2015, 99, 663-671.	0.9	44
125	Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases. Current Pharmaceutical Design, 2015, 21, 1158-1163.	0.9	21
126	Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills. Current Pharmaceutical Design, 2015, 22, 196-213.	0.9	17

#	Article	IF	Citations
127	Intimal pericytes as the second line of immune defence in atherosclerosis. World Journal of Cardiology, 2015, 7, 583.	0.5	23
128	Approach to Reduction of Blood Atherogenicity. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-8.	1.9	11
129	Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease. International Journal of Molecular Sciences, 2014, 15, 12807-12841.	1.8	74
130	Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. Frontiers in Physiology, 2014, 5, 196.	1.3	28
131	Low Density Lipoprotein-Containing Circulating Immune Complexes: Role in Atherosclerosis and Diagnostic Value. BioMed Research International, 2014, 2014, 1-7.	0.9	38
132	Quantitative Assessment of Heteroplasmy of Mitochondrial Genome: Perspectives in Diagnostics and Methodological Pitfalls. BioMed Research International, 2014, 2014, 1-9.	0.9	40
133	Mitochondrial Aging and Age-Related Dysfunction of Mitochondria. BioMed Research International, 2014, 2014, 1-7.	0.9	312
134	The complexity of cell composition of the intima of large arteries: focus on pericyte-like cells. Cardiovascular Research, 2014, 103, 438-451.	1.8	47
135	Diagnostic and Prognostic Value of Low Density Lipoprotein-Containing Circulating Immune Complexes in Atherosclerosis. Journal of Clinical Immunology, 2013, 33, 489-495.	2.0	21
136	Increased Shedding of Microvesicles from Intimal Smooth Muscle Cells in Athero-Prone Areas of the Human Aorta: Implications for Understanding of the Predisease Stage. Pathobiology, 2013, 80, 24-31.	1.9	27
137	Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. Immunology Letters, 2013, 151, 10-22.	1.1	52
138	Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. International Journal of Cardiology, 2013, 166, 747-748.	0.8	8
139	Changes of mitochondria in atherosclerosis: Possible determinant inÂthe pathogenesis of the disease. Atherosclerosis, 2013, 227, 283-288.	0.4	52
140	Vascular Extracellular Matrix in Atherosclerosis. Cardiology in Review, 2013, 21, 270-288.	0.6	96
141	Changes of lysosomes in the earliest stages of the development of atherosclerosis. Journal of Cellular and Molecular Medicine, 2013, 17, 626-635.	1.6	16
142	Intracellular Cholesterol Retentionâ€"New Target for Direct Anti-Atherosclerotic Therapy. Open Journal of Endocrine and Metabolic Diseases, 2013, 03, 9-17.	0.2	0
143	Anti-atherosclerotic Drugs from Natural Products. Natural Products Chemistry & Research, 2013, 1, .	0.2	2
144	Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications. Current Pharmaceutical Design, 2013, 19, 5942-5953.	0.9	29

#	Article	IF	Citations
145	Association of Mitochondrial Genetic Variation with Carotid Atherosclerosis. PLoS ONE, 2013, 8, e68070.	1.1	38
146	Anti-Atherosclerotic Therapy Based on Botanicals. Recent Patents on Cardiovascular Drug Discovery, 2013, 8, 56-66.	1.5	44
147	Novel Monocyte Biomarkers of Atherogenic Conditions. Current Pharmaceutical Design, 2013, 19, 5859-5864.	0.9	17
148	Direct Anti-Atherosclerotic Therapy; Development of Natural Anti-Atherosclerotic Drugs Preventing Cellular Cholesterol Retention. Current Pharmaceutical Design, 2013, 19, 5909-5928.	0.9	37
149	Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy. Current Pharmaceutical Design, 2013, 19, 5954-5962.	0.9	22
150	Association of the level of heteroplasmy of the 15059G>A mutation in the MT-CYB mitochondrial gene with essential hypertension. World Journal of Cardiology, 2013, 5, 132.	0.5	10
151	Mitochondrial Mutations are Associated with Atherosclerotic Lesions in the Human Aorta. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	43
152	Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. Drug Delivery, 2012, 19, 392-405.	2.5	37
153	Widespread distribution of HLA-DR-expressing cells in macroscopically undiseased intima of the human aorta: A possible role in surveillance and maintenance of vascular homeostasis. Immunobiology, 2012, 217, 558-568.	0.8	19
154	Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology, 2012, 217, 476-482.	0.8	103
155	Mitochondrial dysfunction and mitochondrial DNA mutations in atherosclerotic complications in diabetes. World Journal of Cardiology, 2012, 4, 148.	0.5	20
156	Pluronic Block Copolymers Inhibit Low Density Lipoprotein Selfâ€Association. Lipids, 2012, 47, 995-1000.	0.7	8
157	Mutation C3256T of Mitochondrial Genome in White Blood Cells: Novel Genetic Marker of Atherosclerosis and Coronary Heart Disease. PLoS ONE, 2012, 7, e46573.	1.1	27
158	Musashi-1 expression in atherosclerotic arteries and its relevance to the origin of arterial smooth muscle cells: Histopathological findings and speculations. Atherosclerosis, 2011, 215, 355-365.	0.4	9
159	Correlation between lipid deposition, immune-inflammatory cell content and MHC class II expression in diffuse intimal thickening of the human aorta. Atherosclerosis, 2011, 219, 171-183.	0.4	20
160	The Interaction of Plasma Sialylated and Desialylated Lipoproteins with Collagen from the Intima and Media of Uninvolved and Atherosclerotic Human Aorta. Journal of Lipids, 2011, 2011, 1-8.	1.9	8
161	The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids in Health and Disease, 2010, 9, 119.	1.2	81
162	Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension. Hypertension Research, 2009, 32, 433-437.	1.5	56

#	Article	IF	Citations
163	Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study. Acta Diabetologica, 2008, 45, 1-6.	1.2	90
164	Lipid-Lowering Effects of Time-Released Garlic Powder Tablets in Double-Blinded Placebo-Controlled Randomized Study. Journal of Atherosclerosis and Thrombosis, 2008, 15, 334-338.	0.9	68
165	Evaluation of Cell Proliferation in Human Atherosclerotic Lesions. , 2001, 52, 213-218.		2
166	In vivo oxidized low density lipoprotein: degree of lipoprotein oxidation does not correlate with its atherogenic properties. Molecular and Cellular Biochemistry, 1998, 183, 141-146.	1.4	9
167	Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions. Atherosclerosis, 1998, 139, 41-48.	0.4	67
168	Antioxidant content in low density lipoprotein and lipoprotein oxidationin vivoandin vitro. Free Radical Research, 1998, 29, 165-173.	1.5	24
169	The Effects of Antihypertensive Agents on Atherosclerosis-Related Parameters of Human Aorta Intimal Cells. Cardiology, 1998, 89, 111-118.	0.6	12
170	Optimization of the assay for sialic acid determination in low density lipoprotein. Journal of Lipid Research, 1998, 39, 2293-2299.	2.0	15
171	Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis, 1997, 135, 19-27.	0.4	104
172	Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. International Journal of Cardiology, 1997, 62, S67-S77.	0.8	16
173	Effects of garlic on atherosclerosis. Nutrition, 1997, 13, 656-663.	1.1	76
174	Lack of correlation between degree of human plasma low density lipoprotein oxidation and its atherogenic potential. BioFactors, 1997, 6, 139-143.	2.6	4
175	Metabolism of Native and Naturally Occurring Multiple Modified Low Density Lipoprotein in Smooth Muscle Cells of Human Aortic Intima. Experimental and Molecular Pathology, 1997, 64, 127-145.	0.9	57
176	In vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells. Lipids, 1997, 32, 1055-1060.	0.7	44
177	Similarity Between Naturally Occurring Modified Desialylated, Electronegative and Aortic Low Density Lipoprotein. Free Radical Research, 1996, 25, 313-319.	1.5	26
178	Diagnostic value of immune cholesterol as a marker for atherosclerosis. European Journal of Cardiovascular Prevention and Rehabilitation, 1995, 2, 459???466.	1.5	7
179	Naturally Occurring Modified Low Density Lipoproteins Are Similar if Not Identical: More Electronegative and Desialylated Lipoprotein Subfractions. Experimental and Molecular Pathology, 1995, 62, 166-172.	0.9	45
180	Direct Anti-atherosclerosis-related Effects of Garlic. Annals of Medicine, 1995, 27, 63-65.	1.5	57

#	Article	IF	Citations
181	Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease. Coronary Artery Disease, 1993, 4, 379-386.	0.3	50
182	Beta-blockers: propranolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine. Atherosclerosis, 1992, 95, 77-85.	0.4	10
183	Atherogenicity of Anti-LDL Autoantibodies. , 1992, , 91-98.		0
184	Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis, 1991, 86, 153-161.	0.4	113
185	Lipoprotein immune complexes and their role in atherogenesis. Current Opinion in Lipidology, 1991, 2, 329-334.	1.2	10
186	Lipids in cells of atherosclerotic and uninvolved human aorta. Experimental and Molecular Pathology, 1991, 54, 22-30.	0.9	20
187	Atherogenic Factors of Blood: Desialylated LDL and Anti-LDL Autoantibodies. , 1991, , 73-85.		1
188	In vitro models of antiatherosclerotic effects of cardiovascular drugs. American Journal of Cardiology, 1990, 66, 23-28.	0.7	121
189	Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis, 1990, 81, 183-189.	0.4	42
190	Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: Separation from native lipoprotein by affinity chromatography. Biochemical and Biophysical Research Communications, 1990, 167, 1122-1127.	1.0	77
191	Antibody-Like Immunoglobulins G Against Low Density Lipoprotein that Stimulate LIPID Accumulation in Cultured Cells. Advances in Experimental Medicine and Biology, 1990, 285, 399-405.	0.8	6
192	Cholesterol Level in Circulating Immune Complexes as a Marker of Coronary Atherosclerosis. Advances in Experimental Medicine and Biology, 1990, 285, 393-397.	0.8	4
193	Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Experimental and Molecular Pathology, 1989, 50, 337-347.	0.9	67
194	Neutral glycolipids of atherosclerotic plaques and unaffected human aorta tissue. FEBS Journal, 1989, 180, 167-171.	0.2	9
195	Antiatherogenic and antiatherosclerotic effects of mushroom extracts revealed in human aortic intima cell culture. Drug Development Research, 1989, 17, 109-117.	1.4	25
196	Insolubilization of low density lipoprotein induces cholesterol accumulation in cultured subendothelial cells of human aorta. Atherosclerosis, 1989, 79, 59-70.	0.4	29
197	Ganglioside content and composition of cells from normal and atherosclerotic human aorta. Atherosclerosis, 1989, 78, 39-45.	0.4	25
198	Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochemical and Biophysical Research Communications, 1989, 163, 489-494.	1.0	120

#	Article	IF	Citations
199	Atherogenic effects of beta blockers on cells cultured from normal and atherosclerotic aorta. American Journal of Cardiology, 1988, 61, 1116-1117.	0.7	17
200	Cardiovascular Drugs and Atherosclerosis. Journal of Cardiovascular Pharmacology, 1988, 12, S66-S68.	0.8	27
201	Association of low-density lipoprotein with particulate connective tissue matrix components enhances cholesterol accumulation in cultured subendothelial cells of human aorta. Biochimica Et Biophysica Acta - Molecular Cell Research, 1987, 928, 251-258.	1.9	33
202	Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells. American Journal of Cardiology, 1987, 59, 495-496.	0.7	45
203	The gangliosides of adult human aorta: intima, media and plaque. FEBS Journal, 1987, 167, 349-352.	0.2	34
204	Lowâ€Ðensity Lipoprotein Apheresis and Regression of Atherosclerotic Plaque In Vitro. Artificial Organs, 1986, 10, 466-469.	1.0	4
205	Effect of cyclic AMP on lipid accumulation and metabolism in human atherosclerotic aortic cells. Atherosclerosis, 1986, 62, 55-64.	0.4	14
206	?Regression? of atherosclerosis in cell culture: Effects of stable prostacyclin analogues. Drug Development Research, 1986, 9, 189-201.	1.4	21
207	Adult human aortic cells in primary culture: heterogeneity in shape. Heart and Vessels, 1986, 2, 193-201.	0.5	24
208	Intracellular Cholesterol Lowering as Novel Target for Antiâ€Atherosclerotic Therapy. , 0, , .		1
209	Circulating Atherogenic Multiple-Modified Low-Density Lipoprotein: Pathophysiology and Clinical Applications. , 0, , .		0
210	Potential use of buccal epithelium for genetic diagnosis of atherosclerosis using mtDNA mutations. Vessel Plus, 0, , .	0.4	14
211	New markers of atherosclerosis: a threshold level of heteroplasmy in mtDNA mutations. Vessel Plus, 0, , .	0.4	8